In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to disrupt the pre-exposure prophylaxis (PrEP) market with a twice-yearly ...

Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

Gilead Sciences’ inflammation drug prospects have come via deals, and the latest one brings drug candidates for an elusive target that’s in pursuit by a growing number of companies.

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and, now, more deeply than before, into inflammation, penning a major $1.7 billion deal ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to ...